News

Glioblastoma slowdown
Enlarge image

Clinical TrialsSwitzerland

Glioblastoma slowdown

13.08.2012 - Phase III results of Roche's unit Genentech Inc. show that a combination therapy including Avastin can significantly extend progression-free survival of patients with glioblastoma.

The AVAglio study investigating Avastin (bevacizumab) plus radiation and temozolomide chemotherapy (Merck's Temodar) in newly diagnosed brain tumour patients has met its co-primary endpoint of a significant improvement in progression-free survival compared with radiation and temozolomide chemotherapy alone. No new safety findings were observed in, and adverse events were consistent with those seen in previous trials of Avastin across its approved tumour types.

Data for the co-primary endpoint of overall survival are expected in 2013. The double-blind, international trial enrolled 921 patients. Basel-headquartered Roche and Genentech plan to discuss the results with EMA, FDA and other global regulatory authorities.

Avastin is currently approved in the US for adults with glioblastoma who have progressive disease following prior therapy and is only licensed for use as a single therapy and not in combination with other treatments. The product is not approved for glioblastoma in Europe.

http://www.european-biotechnology-news.com/news/news/2012-03/glioblastoma-slowdown.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON10.43 EUR7.08%
  • EVOTEC3.27 EUR4.47%
  • MORPHOSYS78.71 EUR1.88%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • 4SC0.89 EUR-5.32%
  • CYTOS0.28 CHF-3.45%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.14 EUR45.6%
  • FORMYCON10.43 EUR32.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.54 EUR-12.4%
  • CO.DON2.50 EUR-9.1%

TOP

  • SANTHERA92.25 CHF2505.9%
  • CO.DON2.50 EUR140.4%
  • BB BIOTECH183.00 EUR63.5%

FLOP

  • CYTOS0.28 CHF-91.6%
  • 4SC0.89 EUR-48.6%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014